Skip to main content

The independent medical news service

Kidney cancer

21-09-2021 | Oncology | News | Article

Drug-free interval feasible in metastatic RCC

Incorporating a drug-free interval into first-line treatment for metastatic clear cell renal cell carcinoma may not be detrimental to patient survival or quality of life, suggest STAR trial data presented at the ESMO Congress 2021.

17-08-2021 | Oncology | News | Article

FDA approves HIF-2α inhibitor belzutifan for VHL-associated tumors

Read more on this US FDA announcement here

16-08-2021 | Oncology | News | Article

Lenvatinib–pembrolizumab gets FDA nod for first-line advanced RCC

Click through for the details of this decision

16-07-2021 | Oncology | News | Article

Ex vivo tumor platform gives window to PD-1 blockade response

A patient-derived tumor fragment platform has allowed close examination of the early immunologic responses to PD-1 blockade, revealing a relationship between immune cell reactivation and clinical response.

21-06-2021 | Oncology | News | Article

Bacterial product linked to improved metastatic RCC response to nivolumab plus ipilimumab

Preliminary research presented at the 2021 ASCO Annual Meeting suggests that use of a bacterial product might improve response to checkpoint inhibitor therapy in patients with metastatic renal cell carcinoma.

09-06-2021 | Oncology | News | Article

HRQoL data favor lenvatinib–pembrolizumab over sunitinib in advanced RCC

Patients who receive lenvatinib plus pembrolizumab for advanced renal cell carcinoma report similar or better health-related quality of life than those who receive sunitinib, show data from the phase 3 CLEAR trial.

07-06-2021 | Oncology | News | Article

CANTATA: No improvement in advanced RCC outcomes with telaglenastat addition

The combination of telaglenastat and cabozantinib offers no extra benefit over cabozantinib alone in the second- or third-line treatment of advanced clear cell renal cell carcinoma, suggest phase 2 trial results.

04-06-2021 | Oncology | News | Article

KEYNOTE-564 supports adjuvant pembrolizumab use in high-risk RCC patients

Postoperative treatment with pembrolizumab significantly improves the disease-free survival of patients with high-risk, clear cell renal cell carcinoma relative to placebo, show trial data.

26-05-2021 | Oncology | News | Article

First-line immunotherapy benefits transfer to real-world clear cell RCC

Real-world study data show that first-line immunotherapy alone or in combination with targeted therapy is associated with better overall survival than targeted therapy alone in people with metastatic clear cell renal cell carcinoma.

23-04-2021 | Oncology | News | Article

Lenvatinib–everolimus has ‘encouraging activity’ in untreated non-clear cell RCC

Previously untreated patients with advanced non-clear cell renal cell carcinoma could benefit from treatment with lenvatinib plus everolimus, suggests a phase 2 study.

16-04-2021 | Oncology | News | Article

Outliers in link between obesity and poor cancer survival reinforced in meta-analysis

Individuals with obesity tend to have worse cancer survival outcomes than those without obesity, unless they have lung cancer, renal cell carcinoma, or melanoma, show findings of a systematic review and meta-analysis.

07-04-2021 | Oncology | News | Article

Evidence for active surveillance in mRCC grows

Real-world data suggest that active surveillance may be a feasible treatment option for some patients with metastatic renal cell carcinoma.

11-03-2021 | Oncology | News | Article

Tivozanib approved for US patients with refractory advanced RCC

More information about this approval here

09-03-2021 | Oncology | News | Article

RCC obesity paradox holds true in ICI era

Researchers report an association between high BMI and improved outcomes in response to immune checkpoint inhibitors in patients with metastatic renal cell carcinoma.

02-03-2021 | Oncology | News | Article

Cabozantinib–nivolumab receives EMA positive opinion for advanced RCC

Click through to read more

17-02-2021 | Oncology | News | Article

Belzutifan plus cabozantinib shows preliminary activity in metastatic ccRCC

Combination therapy with the HIF-2α inhibitor belzutifan and the multikinase inhibitor cabozantinib shows antitumor activity in people with metastatic clear cell renal cell carcinoma, phase 2 study data show.

16-02-2021 | Oncology | News | Article

Lenvatinib plus pembrolizumab achieve CLEAR survival advantage for clear cell RCC

The CLEAR study has demonstrated a significant progression-free survival gain with use of lenvatinib plus pembrolizumab for the first-line treatment of advanced clear cell renal cell carcinoma.

28-01-2021 | Oncology | News | Article

Baseline variables may predict immunotherapy response in metastatic ccRCC

A number of baseline variables, including age and PD-L1 expression level, may be linked to survival outcomes among people receiving PD-1 or PD-L1 inhibitors for metastatic clear cell renal cell carcinoma, meta-analysis data show.

26-01-2021 | Oncology | News | Article

FDA approves first-line nivolumab–cabozantinib for advanced RCC

Read more about this here

24-12-2020 | Oncology | News | Article

EMA adopts positive opinions for breast, lung, GU cancer indications

Read more about these decisions here

Image Credits